arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

MAIA Biotechnology, Inc.

MAIA
$1.03 ▼ -0.09 (-7.59%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
21 Visible periods
21 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, MAIA Biotechnology, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $62.6M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -31.8% ↘
FCF / Share $-0.11 ↗
Trailing P/E —
Price / Book 3.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

21-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-6.37M
↓ -41.0% —
FCF / Share Free cash flow per share
$-0.11
↑ +5.5% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -1021.6% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.84x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 5 years · 21 quarters